Medite Cancer Valuation
| MDIT Stock | USD 0.0001 0.00 0.00% |
Medite Cancer seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Medite Cancer Diagnostics from analyzing the firm fundamentals such as Current Valuation of 7.44 M, return on equity of -0.74, and Profit Margin of (0.65) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Medite Cancer's price fluctuation is very steady at this time. Calculation of the real value of Medite Cancer Diagnostics is based on 3 months time horizon. Increasing Medite Cancer's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Medite Cancer's intrinsic value may or may not be the same as its current market price of 0.0001, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 | Naive 1.0E-4 |
The intrinsic value of Medite Cancer's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Medite Cancer's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Medite Cancer Diagnostics helps investors to forecast how Medite pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Medite Cancer more accurately as focusing exclusively on Medite Cancer's fundamentals will not take into account other important factors: Medite Cancer Total Value Analysis
Medite Cancer Diagnostics is now forecasted to have valuation of 7.44 M with market capitalization of 520.34 K, debt of 4.91 M, and cash on hands of 90 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Medite Cancer fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
7.44 M | 520.34 K | 4.91 M | 90 K |
Medite Cancer Investor Information
The company has price-to-book ratio of 0.21. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Medite Cancer Diagnostics recorded a loss per share of 0.11. The entity last dividend was issued on the 29th of October 2010. The firm had 1:100 split on the 12th of March 2015. Based on the analysis of Medite Cancer's profitability, liquidity, and operating efficiency, Medite Cancer Diagnostics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Medite Cancer Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Medite Cancer has an asset utilization ratio of 42.7 percent. This implies that the Company is making $0.43 for each dollar of assets. An increasing asset utilization means that Medite Cancer Diagnostics is more efficient with each dollar of assets it utilizes for everyday operations.Medite Cancer Profitability Analysis
The company reported the previous year's revenue of 6.81 M. Net Loss for the year was (6.81 M) with profit before overhead, payroll, taxes, and interest of 162 K.About Medite Cancer Valuation
The pink sheet valuation mechanism determines Medite Cancer's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Medite Cancer Diagnostics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Medite Cancer. We calculate exposure to Medite Cancer's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Medite Cancer's related companies.Medite Cancer Diagnostics, Inc. operates as a medical technology company. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida. Medite Cancer operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 69 people.
8 Steps to conduct Medite Cancer's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Medite Cancer's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Medite Cancer's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Medite Cancer's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Medite Cancer's revenue streams: Identify Medite Cancer's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Medite Cancer's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Medite Cancer's growth potential: Evaluate Medite Cancer's management, business model, and growth potential.
- Determine Medite Cancer's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Medite Cancer's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Medite Cancer Growth Indicators
Investing in growth stocks can be very risky. If the company such as Medite Cancer does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 28.9 M | |
| Retained Earnings | -8.2 M | |
| Shares Float | 17.3 M |
Additional Tools for Medite Pink Sheet Analysis
When running Medite Cancer's price analysis, check to measure Medite Cancer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medite Cancer is operating at the current time. Most of Medite Cancer's value examination focuses on studying past and present price action to predict the probability of Medite Cancer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medite Cancer's price. Additionally, you may evaluate how the addition of Medite Cancer to your portfolios can decrease your overall portfolio volatility.